BILL ANALYSIS

HR7104

NEUTRAL

Immediate Access for the Terminally Ill Act

HR7104 (Immediate Access for the Terminally Ill Act) carries an AI-assessed market impact score of 4/10 with a neutral outlook for investors. This legislation directly affects UnitedHealth Group ($UNH), CVS Health ($CVS), Cigna Group ($CI) and Humana ($HUM) and 5 other tickers. The primary sectors impacted are Healthcare and Finance. View the full bill text on Congress.gov.

4/10

Impact Score

neutral

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR7104 allows terminally ill SSDI beneficiaries to elect expedited benefit payments in exchange for a reduced monthly amount.

The bill shifts the timing of existing Social Security Administration disbursements, not the total amount.

A companion bill (S3648) exists in the Senate, indicating coordinated legislative support.

The bill is in the early committee stage, requiring further legislative action to advance.

How HR7104 Affects the Market

The Immediate Access for the Terminally Ill Act, if enacted, would create a new market for financial products and services designed to assist terminally ill individuals with managing accelerated Social Security benefits. This could present opportunities for financial institutions and insurance companies to develop specialized offerings. While the bill does not directly increase overall Social Security outlays, the change in disbursement timing could influence the financial planning and healthcare spending of a specific demographic. Companies like UnitedHealth Group ($UNH), CVS Health ($CVS), The Cigna Group ($CI), Humana Inc. ($HUM), Molina Healthcare, Inc. ($MOH), and Centene Corporation ($CNC) in the healthcare sector, and Aflac Incorporated ($AFL), Prudential Financial, Inc. ($PRU), and MetLife, Inc. ($MET) in the insurance sector, may explore how to adapt their services to this potential market shift. Recent positive 7-day and 30-day stock performance for several of these companies, such as $UNH (+12.78% 7-day, +6.52% 30-day) and $HUM (+11.29% 7-day, +7.71% 30-day), indicates general market strength in these sectors, though this is not directly attributable to this specific bill at its current stage.

Bill Details

Metric	Value
Bill Number	HR7104
Impact Score	4/10Certainty: Introduced/Referred (+1.0 companion bill) · Financial Magnitude: No explicit funding identified · Strategic Weight: AI qualitative assessment: 4/10 · Market Penetration: 9 companies — very broad impact across 2 sectors
Market Sentiment	neutral
Event Date	January 15, 2026
Affected Sectors	Healthcare, Finance
Affected Stocks	UnitedHealth Group ($UNH), CVS Health ($CVS), Cigna Group ($CI), Humana ($HUM), Molina Healthcare ($MOH), Centene ($CNC), $AFL, $PRU, $MET
Source	View on Congress.gov →

Summary

The Immediate Access for the Terminally Ill Act (HR7104) is in the early stages of the legislative process, having been introduced and referred to committee. This bill aims to allow terminally ill SSDI beneficiaries to receive expedited benefits, which could create a new market for financial products and services catering to this demographic. While the bill does not authorize new funding, it modifies the timing of existing Social Security Administration disbursements.

Full AI Market Analysis

The Immediate Access for the Terminally Ill Act (HR7104) was introduced in the House on January 15, 2026, and subsequently referred to the House Committee on Ways and Means. An identical companion bill, S3648, has been introduced in the Senate and referred to the Committee on Finance. This indicates a coordinated legislative effort, which can increase the probability of a bill advancing. This bill does not authorize or appropriate new funding. Instead, it amends title II of the Social Security Act to allow disabled individuals with specific incurable terminal illnesses, as listed on the Compassionate Allowance list, to receive disability insurance benefits without a waiting period. This means a shift in the timing of existing Social Security Administration disbursements, providing earlier access to benefits for a defined group of beneficiaries. The mechanism is a change in eligibility and payment timing, not an increase in the overall Social Security budget. Structural winners could include financial services companies that develop products tailored to individuals receiving expedited, but reduced, lump-sum or accelerated benefit payments. Insurance companies, particularly those offering life insurance or annuities, might see an opportunity to provide solutions for managing these accelerated benefits. Healthcare providers and managed care organizations could also see an indirect impact as beneficiaries gain earlier access to funds, potentially influencing their healthcare spending decisions. Companies like UnitedHealth Group ($UNH), CVS Health ($CVS), The Cigna Group ($CI), Humana Inc. ($HUM), Molina Healthcare, Inc. ($MOH), and Centene Corporation ($CNC) operate in sectors that could be indirectly affected by changes in beneficiary liquidity and healthcare spending patterns. Life and disability insurers such as Aflac Incorporated ($AFL), Prudential Financial, Inc. ($PRU), and MetLife, Inc. ($MET) may explore new product offerings. Looking at recent market data, several healthcare and insurance companies have shown positive 7-day and 30-day changes. UnitedHealth Group ($UNH) is up +12.78% in the last 7 days and +6.52% in the last 30 days, closing at $305.16. CVS Health ($CVS) is up +8.7% in the last 7 days, closing at $78.07. Humana Inc. ($HUM) is up +11.29% in the last 7 days and +7.71% in the last 30 days, closing at $192.96. Centene Corporation ($CNC) is up +10.35% in the last 7 days, closing at $36.13, though it is down -17.23% over 30 days. The Cigna Group ($CI) and Molina Healthcare, Inc. ($MOH) also show positive 7-day changes. Aflac ($AFL) and MetLife ($MET) have shown modest positive 7-day changes, while Prudential Financial ($PRU) had a slight negative 7-day change. The bill is currently in the early committee stage, and further legislative steps, including committee hearings, markups, and votes in both chambers, would be required for it to advance. Given the early stage of the bill, the timeline for potential enactment is uncertain, but the presence of a companion bill suggests a coordinated effort to move this legislation forward.